Conversely, ceftriaxone pre-treatment of rats prevented the post-stroke decrease in EAAT2 levels, ameliorated neurological deficit 24 h after ischemia and decreased infarct volume [232]. The gene discussed is SLC1A2; the disease is stroke disorder.